Protocol Ledger

NCT03860935 · Phase III · COMPLETED

Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy

Interventional Phase III clinical trial protocol NCT03860935 sponsored by Eidos Therapeutics, a BridgeBio company in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-03-19 Enrollment: 632 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03860935
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)632 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03860935
Protocol FieldVerified Registry Value
NCT IdentifierNCT03860935
Consolidated Lead SponsorEidos Therapeutics, a BridgeBio company
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment632 participants (ACTUAL)
Registered Start Date2019-03-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI